Ralph A. DeFronzo, M.D., Professor and Chief of the Diabetes Division, is world renown for his pioneering work on the pathogenesis and treatment of T2DM, having received the Banting Medal from the American Diabetes Association (ADA) and the Claude Bernard Award from the European Association for the Study of Diabetes (EASD). These are the highest scientific awards given by the ADA and EASD.
Professor Christopher Jenkinson, Ph.D., is a recognized world authority on the genetics of T2DM. Professor Franco Folli, M.D., Ph.D., is a leading expert on the molecular etiology of insulin resistance and oversees a large prospective study in baboons with T2DM to define the mechanisms responsible for beta cell failure.
The seminal studies of Muhammad Abdul-Ghani, M.D., Ph.D., Associate Professor, have helped to define the role of progressive beta cell failure in the evolution from prediabetes to T2DM and to elucidate the contribution of mitochondrial dysfunction in the development of insulin resistance and T2DM.
Devjit Tripathy, M.D., Ph.D., Associate Professor, has focused his basic research on endoplasmic reticulum stress, while his clinical studies have examined novel treatments for impaired glucose tolerance and T2DM.
Bruno Doiron, Ph.D., Assistant Professor, has developed innovative techniques to transfect beta cells in vivo with transcription factors/genes that regulate beta cell growth and insulin secretion.
Curtis Triplitt, PharmD, Associate Professor plays a vital role in supervising our large clinical research program and has a special interest in novel therapies for T2DM. These clinical research activities are conducted on the Barter Research Unit of UT Health San Antonio located in the South Texas Veterans Health Care System and on the Clinical Research Center at the Texas Diabetes Institute. The Clinical Research Center at the TDI is involved in the development of new medications and approaches for the treatment of T2DM.
Luke Norton, Ph.D., Assistant Professor, oversees an active basic research program that focuses on the regulation of SGLT2 and its contribution to renal glucose reabsorption and the role of TCF7C2 in hepatic and adipocyte metabolism.
Franco Folli, M.D., Ph.D., Professor, is a world authority on beta cell regeneration in humans with T2DM and has elucidated the basic molecular mechanisms via which GLP-1 receptor agonists stimulate beta cell proliferation and inhibit apoptosis in primates.
Eugenio Cersosimo, M.D., Ph.D., Professor, has defined the contribution of the kidney in endogenous glucose production and his current research focuses on the role of renal glucose reabsorption in the pathogenesis of T2DM. He also has a major research interest in the mechanisms via which insulin resistance promotes atherogenesis.